Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

To develop a machine learning (ML) algorithm to predict survival probabilities for patients with epithelial ovarian cancer (EOC).Data were obtained from the SEER database for women diagnosed with EOC ...

Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...

New Zealand women with ovarian cancer finally have funded access to bevacizumab. Pharmac’s announcement yesterday comes ten years after the treatment was funded in Australia, and follows a long fight ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer ...

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEM ...

The following highlights showcase the most pivotal, innovative research published across multiple therapeutic areas in ...

Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...